RE: 30p target16 Jul 2024 06:36
I watched and listed the questions & answers.
SP currently in range being accumulated due to overhang can’t be much left at all!
Questions:
1. Could you quickly remind the audience of exactly what vichDx does and its key USPs?
2. What attracted Thermo Fisher Scientific to the technology and how is that relationship progressing?
3. Can you provide an update on the commercialization of the Tovia test, including the Medicaid approval process?
4. Can you provide an update on the other tests in the pipeline, such as Protega and Clava?
5. Can you discuss the services revenue stream the company is building?
6. Can you talk through the company's cash position and runway?
7. What is the outlook for the next 12 months?
Answers:
1. vichDx develops diagnostic tests based on RNA signature technology, focused initially on the kidney transplant market.
2. Thermo Fisher saw the novelty and power of the technology, leading to a licensing deal that is progressing well with technology transfer completed.
3. Tovia is being adopted by 15 centers so far, with growing integration and repeat orders. The company is going through the Medicaid approval process.
4. Protega, the long-term outcomes test, is on track with data expected in H1 2024. Clava for living donors is another product in the pipeline.
5. The company is building a services business around its RNA sequencing expertise and biobank of samples/data.
6. The recent fundraise provides a cash runway through 2026, enabling the company to focus on execution and growth.
7. The next 12 months will be about building on the strong foundations and executing on product development and commercialization.
Sign In
Follow the stocks
